Publications by authors named "E Valassi"
Article Synopsis
- * A study involving 36 women in remission from CS identified specific circulating microRNAs (miRNAs)—specifically miR-28-5p, miR-495-3p, and miR-654-5p—that could serve as potential biomarkers for the condition.
- * Among these, miR-28-5p showed promise as a non-invasive biomarker for identifying CS patients with sarcopenia, demonstrating an 86% sensitivity and a specificity of 69% at a determined cut-off value.
Context: Medical treatment of acromegaly is currently performed through a trial-and-error approach using first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs, with an effectiveness of about 50%, and subsequent drugs are indicated through clinical judgment. Some biomarkers can predict fgSRLs response.
Objective: Here we report the results of the ACROFAST study, a clinical trial in which a protocol based on predictive biomarkers of fgSRLs was evaluated.
Introduction: Growth hormone (GH)-secreting pituitary tumors (GHomas) are the most common acromegaly cause. At diagnosis, most of them are macroadenomas, and up to 56% display cavernous sinus invasion. Biomarker assessment associated with tumor growth and invasion is important to optimize their management.
View Article and Find Full Text PDFManagement of Cushing's syndrome (CS) can be particularly challenging in older patients, compared with younger individuals, due to the lack of several clinical features associated with cortisol excess along with a greater burden of associated comorbidities. Moreover, the interpretation of diagnostic tests could be influenced by age-related physiological changes in cortisol secretion. While mortality is higher and quality of life is more impaired in the elderly with CS as compared with the younger, there is currently no agreement on the most effective therapeutic options in aged individuals, and safety data concerning medical treatment are scanty.
View Article and Find Full Text PDFThe thrombotic risk in Cushing's syndrome-questions, answers, and the algorithm to consider in its assessment: part I-thrombotic risk not related to surgery.
Front Endocrinol (Lausanne)
March 2024
Introduction: Recently, it has been reported that there is a great diversity in strategies used for thromboprophylaxis in patients with Cushing's syndrome (CS). An aim of this review was to discuss these practices in light of the existing data on the thrombotic risk in patients with CS and guidelines for medically ill patients.
Methods: The four relevant topics and questions on thrombotic risk in CS were identified.